Skip to main content
CRDF
NASDAQ Life Sciences

Cardiff Q3: Onvansertib PFS Still Not Reached at 21+ Months; Phase 3 Slated for Q1 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.728
Mkt Cap
$56.604M
52W Low
$0.72
52W High
$3.31
52W Position info
1.0% above low
Off High info
78% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

CRDF is trading near its 52-week low of $0.72 (1.0% above the low).

Summary

Cardiff's Q3 release repeats the 10-Q financials but adds that median PFS is still not reached in the proposed Phase 3 regimen, with patients past 21 months on treatment, as it prepares a registrational trial for a potential Q1 2027 start.


Key Events · Earnings and Guidance · CRDF

  • Onvansertib PFS Still Not Reached

    Median PFS has not been reached in the 30 mg onvansertib + FOLFIRI/bev arm, the proposed Phase 3 regimen, versus approximately 11 months in the combined standard-of-care arms.

  • Patients Past 21 Months on Treatment

    All patients remaining in the 30 mg onvansertib + FOLFIRI/bev arm have exceeded 21 months on treatment, with the longest over 29 months; as of September 28, 2026, 6 patients remain on the FOLFIRI/bev regimen.

  • Phase 3 Start Targeted Q1 2027

    Cardiff is preparing a registrational Phase 3 trial in first-line RAS-mutated mCRC, with a potential start in the first quarter of 2027.

  • Cash Runway to Q3 2027

    As of September 30, 2026, cash, cash equivalents and short-term investments totaled $33.8 million, with $33.9 million of operating cash used in the first nine months; runway is stated to the end of Q3 2027.


Analysis · CRDF · Life Sciences

The financials here rehash the 10-Q filed hours earlier — $33.8M in cash, a $30.4M nine-month net loss, and runway to the end of Q3 2027. What is new is the clinical read: median PFS has still not been reached in the 30 mg onvansertib + FOLFIRI/bev arm versus roughly 11 months for standard of care, and every patient left in that arm has passed 21 months on treatment. For a company trading near its 52-week low with going-concern doubt, that separation is the entire investment case, and management now points to a registrational Phase 3 start as early as Q1 2027. The catch is funding: the Phase 3 will need capital the current $33.8M does not cover, so a raise is the likely next step.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CRDF was trading at $0.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $56.6M. The 52-week trading range was $0.72 to $3.31. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRDF - Latest Insights

CRDF
Nov 12, 2026, 4:20 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.7276
Real-time Price: $0.740 info
Change: +$0.0124 (+2%) info
Market Cap: $56.604M info
CRDF
Nov 12, 2026, 7:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.7695
Real-time Price: $0.740 info
Change: -$0.0295 (-4%) info
Market Cap: $56.604M info
CRDF
Oct 27, 2026, 4:44 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.8988
Real-time Price: $0.740 info
Change: -$0.1588 (-18%) info
Market Cap: $56.604M info
CRDF
Oct 21, 2026, 6:09 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.950
Real-time Price: $0.740 info
Change: -$0.210 (-22%) info
Market Cap: $56.604M info
CRDF
Sep 14, 2026, 9:28 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.24
Real-time Price: $0.740 info
Change: -$0.4981 (-40%) info
Market Cap: $56.604M info